Method Development and Validation for the Simultaneous Determination of Fexofenadine Hydrochloride and Montelukast Sodium in Drug Formulation Using Normal Phase High-Performance Thin-Layer Chromatography

Table 4

Accuracy studies for the determination of (a) FEX and (b) MTKT (𝑛=6).

Excess drug added to the analyte (%)	Theoretical content (ng spot^−1)	Measured conc. ± SD	Recovery (%)	%RSD	SE
(a) FEX
80	4320	4318.25±11.87	99.96	0.27	4.86
100	4800	4794.31±9.47	99.88	0.20	3.88
120	5280	5269.76±4.09	99.81	0.08	1.67
(b) MTKT
80	320	320.24±2.58	100.08	0.80	1.05
100	400	400.89±1.63	100.22	0.40	0.66
120	480	479.57±0.84	99.91	0.18	0.34